Table 1.
Summary of the data from the recent studies on the use of megaprosthesis for the management of massive skeletal defects in proximal humerus.
| Authors | Diagnosis | No of patients | Average age (years) | Average Follow up | Clinical outcome | Radiological Outcome | Complications | Result | Survival |
|---|---|---|---|---|---|---|---|---|---|
| Dubina et al.9 | Tumors | 761 (30 studies) | 45 | 70.5 | MSTS = 74% | – | 17% mechanical failure* 4% infection | 10% revisions | – |
| Schmolders et al.10 | Primary tumors and metastasis | 30 (15 with trevira tube) | 41 | 26 m | EFS = 20 | 12 cranial migration of prosthesis | 2 subluxations | 3 revisions | 83% at one year, 63% at 2 years |
| 1 luxation and infection | |||||||||
| 1 RNP 1 recurrence 3 fractures | |||||||||
| Marulanda et al.11 | Malignancy | 16 (Aortograft mesh) | 51 | 26 m | – | – | 1 superficial wound infection | 1 death from disease | – |
Abbreviations: EFS = Enneking Functional Score, RNP = Radial Nerve Palsy, m = months, *Mechanical failures including prosthetic loosening, fracture, and dislocation, CPS = Compliant Pre-stress Device, GH = Glenohumeral,PH = Proximal Humerus, SOH = Shaft of Humerus, DH = Distal Humerus.